Mesothelioma Cancer Centers

The Mayo Clinic has experience treating patients with malignant mesothelioma and has a deep understanding of how challenging a mesothelioma diagnosis can be for patients and loved ones.

The Mayo Clinic’s mesothelioma treatment plan depends on the patient. Their physicians understand that many cases are diagnosed in the advanced stages, in which case patients may want to focus solely on palliative care to improve their symptoms and live the highest quality of life possible. For those that are willing to undergo any treatment, the Mayo Clinic is experienced with mesothelioma surgery (including pleurodesis, pleurectomy, extrapleural pneumonectomy and surgery with HIPEC), chemotherapy, radiation therapy, immunotherapy and targeted therapy.

Such treatments may occur within the Mayo Clinic Thoracic Surgery Division, which was founded in 1915. This division is currently one of the largest in the country. The staff includes five board-certified general chest surgeons who provide comprehensive diagnosis and surgical care to cancer patients with diseases of the chest wall and mediastinum, diaphragm, esophagus, lungs and trachea. Pathologists, oncologists, diagnostic specialists and surgeons assist in the diagnosis and treatment of mesothelioma.

Patients may have the option to forgo standard mesothelioma treatments and try alternative options with guidance from their Mayo Clinic physician. Experimental treatments are available to eligible patients through clinical trials conducted through the Mayo Clinic.

The Mayo Clinic has multiple locations with their Arizona, Minnesota and Florida campus locations, offering care to patients across the United States. The non-profit institution that treats more than half a million patients annually. The staff includes more than 3,300 physicians, scientists, and researchers in addition to 46,000 allied health-care workers at Mayo Clinic sites throughout the nation.

Specializations:

• Chemotherapy
• Immunotherapy
• Mesothelioma
• Radiation
• Surgery
• Targeted therapy

Accreditations:

• American Nurses Credentialing Center Magnet Recognized
• National Cancer Institute Comprehensive Cancer Center designation
• U.S. News Best Hospitals Honor Roll

Mesothelioma Clinical Trials at Mayo Clinic Cancer Center

The following clinical trials are in progress or actively recruiting participants at Mayo Clinic Cancer Center:

• Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

  Conditions:	Mesothelioma
  Last Updated:	July 18, 2019
  Status:	Recruiting

• Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

  Conditions:	Mesothelin Positive; Pleural Malignant Mesothelioma
  Last Updated:	July 17, 2019
  Status:	Recruiting

• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

  Conditions:	Biphasic Mesothelioma; Epithelioid Mesothelioma; Stage I Pleural Malignant Mesothelioma AJCC v7; Stage IA Pleural Malignant Mesothelioma AJCC v7; Stage IB Pleural Malignant Mesothelioma AJCC v7; Stage II Pleural Malignant Mesothelioma AJCC v7; Stage III Pleural Malignant Mesothelioma AJCC v7
  Last Updated:	July 4, 2019
  Status:	Recruiting

• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

  Conditions:	Mesothelioma
  Last Updated:	July 1, 2019
  Status:	Active, not recruiting

• Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

  Conditions:	Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm
  Last Updated:	June 10, 2019
  Status:	Recruiting

Sources